Profile | GDS2987 / GI_27734908-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 15.9 | 48 |
GSM215244 | HMVEC_vehicle_rep2 | 28.4 | 56 |
GSM215253 | HMVEC_vehicle_rep3 | 9.4 | 31 |
GSM215254 | HMVEC_atorvastatin_rep1 | 5.8 | 16 |
GSM215282 | HMVEC_atorvastatin_rep3 | 21.5 | 45 |
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 34.9 | 55 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 48.5 | 65 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | 23.8 | 60 |
GSM215295 | HMVEC_SLx2119_rep2 | 26.5 | 47 |
GSM215296 | HMVEC_SLx2119_rep3 | 9.6 | 16 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 20.1 | 31 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 17.9 | 30 |
GSM215312 | PASMC_atorvastatin_rep2 | 15.1 | 24 |
GSM215313 | PASMC_atorvastatin_rep3 | 51.1 | 59 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 38.9 | 54 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | ||
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 17.8 | 31 |
GSM215328 | PASMC_SLx2119_rep2 | 3.9 | 7 |
GSM215329 | PASMC_SLx2119_rep3 | 6.9 | 14 |
GSM215330 | Fibroblasts_vehicle_rep1 | 25.9 | 50 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 2.3 | 8 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 8.8 | 24 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 18.1 | 45 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 20.7 | 45 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 15.2 | 45 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 25.1 | 59 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | ||
GSM215339 | Fibroblasts_SLx2119_rep1 | 23 | 54 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 | 34.2 | 61 |